SAB Biotherapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. SAB Biotherapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91% to $2,238,991. Profit margin reached -1885%. Total operating expenses were $40,314,311.
Profit Margin
| 2019 | 3.44M | -9.41M | -273.62% |
|---|---|---|---|
| 2020 | 55.23M | 20.11M | 36.42% |
| 2021 | 60.87M | -17.44M | -28.66% |
| 2022 | 23.90M | -18.74M | -78.4% |
| 2023 | 2.23M | -42.19M | -1884.5% |
SABSW Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 2.23M | 23.90M | 60.87M | 55.23M | 3.44M |
Cost of revenue | 3.74M | 3.29M | 1.65M | 0 | 0 |
Gross profit | -1.50M | 20.61M | 59.22M | 55.23M | 3.44M |
Operating exp. | |||||
Research and development | 16.51M | 36.43M | 57.18M | 27.90M | 8.01M |
Selling and marketing | -3.74M | 0 | 0 | 0 | 0 |
Total operating expenses | 40.31M | 28.91M | 13.39M | 34.68M | 12.11M |
Operating income | -38.07M | -28.91M | -13.39M | 20.55M | -8.67M |
Other income (expenses), net | -4.11M | 10.20M | -3.75M | -439.02K | -312.74K |
Income before tax | -42.19M | -18.71M | -17.14M | 20.11M | -8.98M |
Income tax expense | 0 | 25.62K | 299.94K | 473.14K | 431.07K |
Net income | -42.19M | -18.74M | -17.44M | 20.11M | -9.41M |
Earnings per share | |||||
Basic EPS | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
Diluted EPS | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| Data source | Data source | Data source | Data source |